📋 Tender Overview
Project Number
51629
Company Name
Hikma Finance USA LLC
Date ESRS Disclosed
Aug 19, 2025
Country
Jordan
Region
Middle East
Last Updated Date
Environmental Category
B - Limited
Status
Active
Previous Events
Approved : Jun 30, 2025
Signed: Jul 3, 2025
Invested: Jul 10, 2025
Sector
Q-B - Retail
Industry
other
Department
Regional Industry MAS MCT
Project Description
Hikma Pharmaceuticals PLC ( Hikma or the Company or together with its subsidiaries the Group ) is a pharmaceutical company incorporated in the United Kingdom (UK) and listed on the London Stock Exchange. While the Group was founded in Jordan in 1978, Hikma has expanded its footprint with successful operations across the Middle East and North Africa (MENA) region, North America and Europe with 29 manufacturing plants in 10 countries. Out of 20 manufacturing plants in the MENA region, there are five plants in the Middle East (four in Jordan and one in the Kingdom of Saudi Arabia - KSA) which are US Food and Drug Administration (FDA) inspected. Hikma’s business lines include branded, injectable and generic pharmaceuticals.
IFC provided a financing package (the Financing Package ) to Hikma Finance USA LLC (the Borrower ), a wholly owned subsidiary of Hikma. Proceeds of the IFC Loan (as defined below) and the Bond (as defined below) which, for the avoidance of doubt, is limited to IFC’s subscription of US$50 million in the Bond, will be used to support the Company’s general corporate purposes including acquisitions, capital expenditure, working capital needs, and any investment in research and development in the Middle East region, as well as debt refinancing of the Group (the Project ). The Financing Package will primarily support Hikma’s existing operations in the Middle East region, including but not limited to facilities in Jordan (five manufacturing plants and two R&D centers) and KSA (three manufacturing plants and one R&D center).
The Financing Package entails (i) a 6-year senior unsecured A loan of US$250 million, to the Borrower – processed under IFC project Hikma Loan 2025 (#51629) (the IFC Loan ); and (ii) a subscription of US$50 million in Hikma Finance’s US$500 million bond (the Bond ), in which IFC played an anchoring role – processed under IFC project Hikma Bond (#51148).
Hikma is a long-standing IFC client since 1987 whereby support was primarily provided to the Company’s investments in the MENA region including financing of acquisitions in Algeria, Tunisia, Morocco and Egypt. IFC has two active investments with the Group, Hikma Expansion (#37324) and RSE Hikma (#44224), and its environmental and social (E&S) performance is satisfactory.
Overview of IFC's Scope of Review
IFC’s review of this project consisted of site visits in June 2025 to two Hikma facilities in the Middle East region. These two facilities, being the largest in Jordan and Kingdom of Saudi Arabia (KSA), were sele
